Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial

Nomathemba Chandiwana, Chelsea Kruger, Hilary Johnstone, Mohamed Farouk Chughlay, Chung Ju, Byungsu Kim, Yengiwe Dineka, Sarah Arbe-Barnes, Robert Miller, Andrew Owen, Andrew Hill, Daniel Windgassen, Nada Abla, Anne Claire Marrast, Stephan Duparc, Willem Daniel Francois Venter

Open source

DOI
10.1016/j.ebiom.2022.104322
Published
2022-12
Container
eBioMedicine
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ebiom.2022.104322,
  title = {Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial},
  author = {Nomathemba Chandiwana and Chelsea Kruger and Hilary Johnstone and Mohamed Farouk Chughlay and Chung Ju and Byungsu Kim and Yengiwe Dineka and Sarah Arbe-Barnes and Robert Miller and Andrew Owen and Andrew Hill and Daniel Windgassen and Nada Abla and Anne Claire Marrast and Stephan Duparc and Willem Daniel Francois Venter},
  year = {2022},
  journal = {eBioMedicine},
  doi = {10.1016/j.ebiom.2022.104322},
  url = {https://doi.org/10.1016/j.ebiom.2022.104322}
}

RIS

TY  - JOUR
TI  - Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial
AU  - Nomathemba Chandiwana
AU  - Chelsea Kruger
AU  - Hilary Johnstone
AU  - Mohamed Farouk Chughlay
AU  - Chung Ju
AU  - Byungsu Kim
AU  - Yengiwe Dineka
AU  - Sarah Arbe-Barnes
AU  - Robert Miller
AU  - Andrew Owen
AU  - Andrew Hill
AU  - Daniel Windgassen
AU  - Nada Abla
AU  - Anne Claire Marrast
AU  - Stephan Duparc
AU  - Willem Daniel Francois Venter
PY  - 2022
JO  - eBioMedicine
DO  - 10.1016/j.ebiom.2022.104322
UR  - https://doi.org/10.1016/j.ebiom.2022.104322
ER  - 

APA

Chandiwana, N., Kruger, C., Johnstone, H., Chughlay, M. F., Ju, C., Kim, B., Dineka, Y., Arbe-Barnes, S., Miller, R., Owen, A., Hill, A., Windgassen, D., Abla, N., Marrast, A. C., Duparc, S., & Venter, W. D. F. (2022). Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial. eBioMedicine. https://doi.org/10.1016/j.ebiom.2022.104322

Source records